Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of Staccato alprazolam for stereotypical prolonged seizures
2023-508868-30-00Phase 3Authorised
- Sponsor
- UCB
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 3, open-label trial of alprazolam in epilepsy (2 arms), sponsored by UCB. Primary endpoints: Frequency of treatment-emergent adverse events, Frequency of TEAEs leading to withdrawal and 1 more. Planned start Sep 2022; status: authorised.
02
Drugs
alprazolam
03
Conditions
epilepsy
Beyond the preview
Go deeper on 2023-508868-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508868-30-00.